Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients-Reference-Cited by-同舟云学术

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Published:2013-10-03 Issue:14 Volume:122 Page:2412-2424
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Chang Betty Y.¹,Francesco Michelle¹,De Rooij Martin F. M.²,Magadala Padmaja¹,Steggerda Susanne M.¹,Huang Min Mei¹,Kuil Annemieke²,Herman Sarah E. M.³,Chang Stella¹,Pals Steven T.²,Wilson Wyndham³,Wiestner Adrian³,Spaargaren Marcel²,Buggy Joseph J.¹,Elias Laurence¹

Affiliation:

1. Research Department, Pharmacyclics, Inc., Sunnyvale, CA;

2. Pathology Department, Academic Medical Center, Amsterdam, The Netherlands; and

3. Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

Abstract

Key Points MCL cells are mobilized into the peripheral blood of patients treated with the BTK inhibitor ibrutinib. Ibrutinib dose-dependently inhibits BCR- and chemokine-mediated adhesion and migration of MCL cells.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/14/2412/1370092/2412.pdf

Reference53 articles.

1. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.;Pérez-Galán;Blood,2011

2. Mantle cell lymphoma: a clinicopathologic study of 80 cases.;Argatoff;Blood,1997

3. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.;Hoster;Blood,2008

4. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells.;Burger;Leuk Lymphoma,2002

5. Stromal gene signatures in large-B-cell lymphomas.;Lenz;N Engl J Med,2008

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CCL17, CCL22 and their receptor CCR4 in hematologic malignancies;Discover Oncology;2024-09-06

2. Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis;Blood Advances;2024-08-29

3. Leveraging altered lipid metabolism in treating B cell malignancies;Progress in Lipid Research;2024-07

4. Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib;Hematological Oncology;2024-06-07

5. The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma;Leukemia;2024-03-07